Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study

Pfizer Inc. and Astellas Pharma announced final Phase 3 EMBARK study results, revealing that XTANDI (enzalutamide) combined with leuprolide significantly reduced the risk of death by 40.3% in men with non-metastatic hormone-sensitive prostate cancer and high-risk biochemical recurrence. This makes XTANDI the first androgen receptor inhibitor-based regimen to demonstrate an overall survival benefit in this patient population, with an 8-year survival rate of 78.9% versus 69.5% for leuprolide alone, reinforcing its therapeutic value and market potential.

Analysis

Pfizer Inc. and Astellas Pharma U.S. Inc. announced compelling final Phase 3 EMBARK study results for XTANDI (enzalutamide), demonstrating a significant overall survival benefit. The combination of XTANDI plus leuprolide reduced the risk of death by 40.3% compared to leuprolide alone in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with biochemical recurrence (BCR) at high risk for metastasis. This positions XTANDI as the first and only androgen receptor inhibitor-based regimen to show an overall survival benefit in this specific patient population.

The 8-year overall survival rate for patients receiving XTANDI plus leuprolide was 78.9%, a notable improvement over the 69.5% observed for leuprolide alone. While XTANDI monotherapy showed a numerical improvement in overall survival, it did not achieve statistical significance. This robust efficacy data significantly strengthens XTANDI's therapeutic profile and market differentiation within the prostate cancer treatment landscape.

The safety profile of XTANDI remained consistent with prior analyses, with no new safety signals identified, primarily reporting common adverse events such as hot flashes and fatigue. This favorable risk-benefit assessment, combined with the substantial overall survival data, enhances the drug's commercial appeal and potential for broader adoption. The positive results are expected to support increased market penetration and expand its use within the high-risk nmHSPC patient segment, building on its existing approvals in over 80 countries.

Key Decisions for Investors

• Investors should consider the significant overall survival benefit demonstrated by XTANDI as a strong positive for Pfizer's oncology pipeline and revenue outlook.
• Monitor the commercial uptake and market penetration of XTANDI in the high-risk nmHSPC population, as this data could drive increased prescription volume and market share.
• Evaluate the long-term competitive landscape in prostate cancer treatments, although XTANDI currently holds a unique position with this overall survival data.